Biotech Values

[rkrw]

It was public that they had to repay a certain amount, the amount wasn't known.

$40M (my est) isn't much. I think it will be repaid within 2 quarters. I don't consider it a big deal since it's non recourse debt and will be repaid quickly.

What happens with Teva is obviously irrelevant to the debt. If Teva were approved soon, tack on a year. If not, I suspect it may be gone by the end of the year.